Pure Global
NCT06355310

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

Ann & Robert H Lurie Children's Hospital of Chicago·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Non-Alcoholic Fatty Liver Disease
Drug/Device/Intervention
Empagliflozin 10 MG
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Timeline & enrollment
Phase
Phase 2
Start date
May 20, 2024
End date
Dec 31, 2028
Enrollment
40 participants
Primary outcome

Hepatic Fat

Summary

This study is a randomized, double-blind, placebo-controlled trial specifically designed to
 evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for
 treating NAFLD in adolescents with obesity.

ICD-10 classifications
Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06355310
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06355310 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.